Clinical Trial Update: Prevalence and Risk Factors in Unipolar Depression Patients Without Remission After One Antidepressant Trial

View source ↗

Summary

AstraZeneca-sponsored study completed, assessing the prevalence and risk factors in patients with major depressive disorder who did not remit after a single ant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Snippet

Sponsor: AstraZeneca | Conditions: Non-psychotic Unipolar Major Depression | Status: COMPLETED